

1 DR. BURCİN BEKEN (Orcid ID: 0000-0001-7677-7690)

2

3 Article type: News and Views: Groundbreaking discoveries in Immunology

4 **Groundbreaking discoveries in Immunology**

5 **Title:**

6 Single-cell RNA analysis: guiding the treatment of DIHS/DRESS

7 Authors: Burcin Beken^a, Alessandra Arcolaci^b, Rodrigo Jimenez-Saiz^{c,d,e}

8 ^aDepartment of Pediatric Allergy & Immunology, Kanuni Sultan Suleyman Training and
9 Research Hospital, Istanbul, Turkey

10 ^bAsthma Center & Allergy Unit, Borgo Roma University & General Hospital, Verona, Italy

11 ^cDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC,
12 Madrid, Spain

13 ^dMcMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular
14 Medicine, McMaster University, Hamilton, Ontario, Canada

15 ^eFaculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain

16

17 *Correspondence to: Burcin Beken. Department of Pediatric Allergy & Immunology, Kanuni
18 Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.

19 e-mail: burcinbeken@gmail.com

20 **Keywords:** DIHS; DRESS; severe cutaneous adverse reaction, SCAR; single-cell RNA
21 sequencing.

22 **Abbreviations:** DEGs, differentially expressed genes; DIHS/DRESS, drug induced
23 hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms; HHV,
24 human herpesvirus; PBMCs, peripheral blood mononuclear cells; scRNA-seq, single cell RNA-
25 sequencing; SM, smooth muscle; SMX, sulfamethoxazole; TMP, trimethoprim; atopic
26 dermatitis, AD; SCARS, severe cutaneous adverse reactions

27

28 **Main text:**

29 Drug-induced hypersensitivity syndrome (DIHS) —also termed as drug reaction with
30 eosinophilia and systemic symptoms (DRESS)— is a potentially lethal inflammatory disease
31 associated with human herpesvirus (HHV) reactivation. DIHS/DRESS is classified within a
32 group of syndromes named severe cutaneous adverse reactions (SCARs), including acute
33 generalized exanthematous pustulosis and Stevens-Johnson syndrome/toxic epidermal
34 necrolysis. SCARs are delayed type IV hypersensitivity reactions mainly characterized by T-
35 cell activation. The pathophysiology of DRESS is still poorly understood.¹ The proposed
36 mechanisms implicated in its pathogenesis include drug detoxification enzyme abnormalities,
37 sequential reactivation of herpesviruses (cytomegalovirus, Epstein-Barr virus, HHV-6 and -7),
38 and genetic predisposition related to certain human leukocyte antigen alleles. The limited
39 knowledge of the mechanisms and pathways underlying the pathology of DRESS present an
40 important treatment hurdle.

41 Over the last few years, targeting specific immunological pathways has become a promising
42 approach to treat complex inflammatory diseases. In that regard, single-cell RNA sequencing
43 (scRNA-seq) provides individual cell information at unprecedented resolution. This enables the
44 analysis of cell lineage trajectories, cell-cell and cell-microenvironment interactions as well as
45 the identification and discovery of new cell types or phenotypes, which all inform about
46 pathogenic mechanisms.^{2,3} For example, He *et al.* conducted a novel study using scRNA-seq
47 analysis in atopic dermatitis (AD) and showed a novel fibroblast population directing type 2
48 immune responses in lesional skin of AD patients.⁴

49 Kim *et al.*⁵ have recently reported an in-depth study of a DIHS/DRESS patient who was treated
50 successfully with the guidance of scRNA-seq. A 44-year-old patient presented with
51 trimethoprim/sulfamethoxazole-induced DIHS/DRESS. In addition, the patient had generalized
52 exfoliative dermatitis and uncontrolled systemic symptoms despite prednisone, etanercept,
53 intravenous immunoglobulin, cyclosporine, and mycophenolate mofetil treatment. The analysis
54 of skin-derived cells of this patient, in comparison with those of healthy controls (HCs),
55 revealed an inflammatory state with relative abundance of keratinocytes and immune cells.
56 Lymphocytes exhibited the greatest transcriptomic changes with T cell predominance and
57 upregulation of genes involved in proliferation (MKI67), migration (CCR10), activation
58 (IL2RG) and signaling pathways (JAK3 and STAT1).

59 The scRNA-seq analysis of peripheral blood mononuclear cells (PBMCs) showed a
60 predominance of CD4⁺ and CD8⁺ subclusters and CCR4⁻ and CCR10-expressing T cells.

61 Moreover, central memory CD4⁺ T cells were enriched with DNA from HHV6b. In contrast to
62 the observation in the skin, *JAK* and *STAT* genes were not detected in an unsupervised manner
63 when the whole PBMC lymphocyte cluster was compared between DiHS/DRESS and HCs.
64 This shows that the local site of inflammation (skin) was optimal for detecting targetable
65 pathways. Altogether, these results led to the identification of potential therapeutic targets for
66 treating this DIHS/DRESS patient, namely the JAK-STAT pathway and the viral infection. The
67 patient achieved disease control after 2 weeks of treatment with tofacitinib (a JAK1 and JAK3
68 inhibitor) plus valgancyclovir (an antiviral).


69 These findings indicate that single-cell omic-based approaches as scRNA-seq might be a
70 powerful means for directing patient care in diseases with a complex inflammatory
71 pathophysiology as SCARs. Drug allergy apart, scRNA-seq has been also applied in allergic
72 asthma. For example, Tibbit *et al.* showed distinct T helper cell subsets in a mouse model of
73 house dust mite-induced asthma (REF). In another study, conducted by Vieira Braga *et al.* in
74 asthmatic patients and HCs, novel subsets were identified of tissue-resident memory T cells and
75 mucus ciliated cells (REF).

76 Although scRNA-seq has been progressively optimized (reduction of costs and number of cells
77 required for analysis),^{2,3} there are still difficulties that preclude its implementation in the clinical
78 practice such as the need for tissue sampling (REF-soumelis) and the complexity of data
79 analysis and interpretation (REF- by Rostom). The increasing use of techniques such as scRNA-
80 seq, or alike, will likely enlighten the understanding of the pathophysiology of
81 allergic/immunological diseases, thus enabling the development of targeted therapies.

82 **Acknowledgements:** We recognise Dr. Anna Globinska for graphic design of the manuscript

83 **Funding information:** RJS is supported by Ministerio de Economía y Competitividad (IJCI-
84 2016-27619).

85 **Conflicts of interest statement:** The authors declare that they have no conflicts of interest in
 86 relation to this manuscript.



87 **Figure 1:** scRNA-seq analysis guided successful therapeutic intervention in a patient with
 88 refractory DIHS/ DRESS. A 44 year-old male patient with TMP/SMX-induced DIHS/DRESS
 89 and progression to TEN-like rash and subsequent generalized exfoliative dermatitis and
 90 uncontrolled systemic symptoms was evaluated to find a potential therapeutic target. Five age-
 91 and sex- matched healthy volunteers were enrolled as a control. Both skin biopsy specimens
 92 and PBMCs were used for scRNA-seq analysis. Four immunological pathways were revealed
 93 at the end of a complex set of analysis: cell proliferation, JAK-STAT pathway, chemokine
 94 receptors and HHV6b proliferation in T lymphocytes with central memory type. Targeting
 95 JAK-STAT pathway with tofacitinib and HHV6b proliferation with valgancyclovir achieved
 96 disease control after 2 weeks of treatment. Pre- and post- treatment scRNA seq analysis of
 97 PBMCs revealed a reduction of CCR4- and CCR10-expressing CD4+ and CD8+ T cells with
 98 proliferative gene signatures consistent with flow cytometry analysis.

99

100 **References**

- 101 1) Bellón T. Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. *Drug Saf.*
102 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2.
- 103 2) Tang F, Barbacioru C, Wang Y, et al. mRNA-Seq whole-transcriptome analysis of a single
104 cell. *Nat Methods.* 2009;6(5):377-382. doi:10.1038/nmeth.1315.
- 105 3) Olsen TK, Baryawno N. Introduction to Single-Cell RNA Sequencing. *Curr Protoc Mol*
106 *Biol.* 2018;122(1):e57. doi:10.1002/cpmb.57.
- 107 4) He H, Suryawanshi H, Morozov P, et al. Single-cell transcriptome analysis of human skin
108 identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic
109 dermatitis. *J Allergy Clin Immunol.* 2020;145(6):1615-1628. doi:10.1016/j.jaci.2020.01.042.
- 110 5) Kim D, Kobayashi T, Voisin B, et al. Targeted therapy guided by single-cell transcriptomic
111 analysis in drug-induced hypersensitivity syndrome: a case report. *Nat Med.* 2020;26(2):236-
112 243. doi:10.1038/s41591-019-0733-7.
- 113
- 114 Tibbitt CA, Stark JM, Martens L, et al. Single-Cell RNA Sequencing of the T Helper Cell
115 Response to House Dust Mites Defines a Distinct Gene Expression Signature in Airway Th2
116 Cells. *Immunity.* 2019;51(1):169-184.e5. doi:10.1016/j.immuni.2019.05.014.
- 117
- 118 Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell
119 states in health and in asthma. *Nat Med.* 2019;25(7):1153-1163. doi:10.1038/s41591-019-0468-
120 5.
- 121 Seumois G, Vijayanand P. Single-cell analysis to understand the diversity of immune cell types
122 that drive disease pathogenesis. *J Allergy Clin Immunol.* 2019;144(5):1150-1153.
123 doi:10.1016/j.jaci.2019.09.014.
- 124 Rostom R, Svensson V, Teichmann SA, Kar G. Computational approaches for interpreting
125 scRNA-seq data. *FEBS Lett.* 2017;591(15):2213-2225. doi:10.1002/1873-3468.12684.
- 126 Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. *J Am*
127 *Acad Dermatol.* 2013;68(5):693.e1-708. doi:10.1016/j.jaad.2013.01.033.